National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Apalutamide (Erleada®). HTA ID: 20010

Apalutamide is indicated for adult men for the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 26/02/2020
Rapid review completed 23/03/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of apalutamide for this indication compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 24/03/2020
Pre-submission consultation with Applicant 15/06/2020
Full HTA submission received from Applicant 20/04/2021
Preliminary review sent to Applicant 01/11/2021
NCPE assessment re-commenced 26/11/2021
Factual accuracy check sent to Applicant 09/02/2022
NCPE assessment re-commenced 17/02/2022
NCPE assessment completed 03/03/2022
NCPE assessment outcome The NCPE recommends that apalutamide (Erleada®) in combination with androgen deprivation therapy be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.